Best Immunotherapy Companies in Seattle, United States
The 32 best Immunotherapy companies in Seattle, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Umoja Biopharma.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Seattle
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Umoja Biopharma Developer of cancer therapeutics | $263M | 21 mo ago | Series C | 168 | 2019 | Michael Jensen Co-Founder | 132 patents Lentiviral CAR gene delivery and scalable stem‑cell manufacturing platforms | — |
| 2 | Silverback Therapeutics Stealth mode immuno-oncology biotech startup | $211M | 73 mo ago | Public | 17 | 2016 | Peter Thompson Co-Founder | 143 patents Novel small‑molecule inhibitors and antibody‑drug conjugates targeting cancer biomarkers | — |
| 3 | Outpace Bio Developer of T-cell therapies for cancer treatment | $200M | 27 mo ago | Series B | 48 48 → 73 (+52%) | 2020 | Scott Boyken Co-Founder | — | — |
| 4 | Callio Therapeutics Developer of multi-payload antibody-drug conjugates for cancer treatment | $187M | 20 mo ago | Series A | — | 2024 | Jerome Kirkup Co-Founder & Chief Scientific Officer | — | — |
| 5 | OncoResponse Developer of immunotherapies for the treatment of cancer 64Funding top 20%Moat top 21%Patents top 24%Innovation top 27% All 8 signals ▾Fundingtop 20% Moattop 21% Patentstop 24% Innovationtop 27% Growthtop 28% Talentbottom 49% Globalbottom 42% Marketbottom 38% Funding: Raised $144M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 18 mo ago | Series D | 33 | 2015 | Clifford Stocks Founder & CEO | 56 patents Therapeutic anti‑LILRB2 antibodies for cancer immunotherapy and combination regimens | — |
| 6 | Just Biotherapeutics Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs | $124M | 101 mo ago | Acquired | 79 | 2014 | — | 36 patents Protein structure prediction, purification optimization, and high-throughput physico-chemical profiling | — |
| 7 | VentiRx Developing small molecule product candidates targeting Toll-like receptor 8 (TLR8) for cancer | $120M | 145 mo ago | Acquired | 15 | 2006 | — | — | — |
| 8 | Kineta Developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases | $104M | 52 mo ago | Acquired | 12 | 2008 | — | 217 patents Discovery of heterocyclic small‑molecule inhibitors of PIKfyve kinase for therapeutic use. | — |
| 9 | immune design Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases. | $101M | 149 mo ago | Acquired | 50 | 2008 | — | 256 patents Viral vector-based gene delivery platforms for cancer immunotherapy and vaccine development | — |
| 10 | Bonum Therapeutics Manufacturer of cytokine based drugs 45Funding top 22%Talent bottom 49%Tech bottom 45%Global bottom 43% All 5 signals ▾Fundingtop 22% Talentbottom 49% Techbottom 45% Globalbottom 43% Marketbottom 36% Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $93M | 7 mo ago | Series B | 54 | 2021 | John Mulligan Founder & CEO | — | — |
| 11 | Curevo Developer of vaccines for the treatment of various diseases 29Funding top 25%Talent top 41%Moat top 43%Patents top 48% All 9 signals ▾Fundingtop 25% Talenttop 41% Moattop 43% Patentstop 48% Techtop 50% Innovationbottom 45% Globalbottom 39% Marketbottom 22% Newsbottom 18% Funding: Raised $86.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: Analyst team rating 4/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 29/100 | $86M | 20 mo ago | Series B | 8 | 2017 | George Simeon CEO | 3 patents Formulating herpes zoster preventive vaccines and combination immunogenic vaccine technologies. | — |
| 12 | Theraclone Sciences Discovering human monoclonal antibodies for safe and effective therapeutic product development | $61M | 138 mo ago | Series B | 19 | 2004 | Clifford J Stocks CEO | 225 patents Broadly neutralizing anti‑HIV‑1 envelope glycoprotein monoclonal antibody therapeutics | — |
| 13 | VLST Corporation Online slot gaming site with high RTP and maxwin opportunities | $60M | 244 mo ago | Deadpooled | 13 | 2004 | Craig Smith Founder | 10 patents Therapeutic antibody engineering targeting CC chemokines for immune modulation | — |
| 14 | Aptevo Therapeutics Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology | $57M | 19 mo ago | Public | 45 45 → 56 (+24%) | 2016 | Marvin White President and CEO | — | — |
| 15 | Immusoft Developer of programmed B cell therapies for protein delivery | $44M | 29 mo ago | Series B | 20 | 2009 | Matthew Scholz Founder | 66 patents Engineered B cells as living factories for in vivo delivery of therapeutic proteins | — |
| 16 | Allozyne Protein therapeutics for CNS diseases such as multiple sclerosis. | $40M | 158 mo ago | Acqui-Hired | 6 | 2005 | Dee Datta Ex-Co-Founder | 39 patents Engineered eukaryotic cell lines for non‑natural amino acid peptide and nucleic acid production | — |
| 17 | Good Therapeutics Developer of protein-based drugs for cancer | $37M | 58 mo ago | Acquired | 23 | 2016 | — | — | — |
| 18 | HDT Bio Developer of immunotherapy for the treatment of cancer & infectious diseases | $31M | 17 mo ago | Seed | 32 32 → 54 (+69%) | 2018 | — | — | — |
| 19 | Etubics Therapeutic vaccines for cancer | $23M | 145 mo ago | Funding Raised | 14 | 2005 | — | 160 patents Adenovirus vector manufacturing for multi‑antigen vaccines and cancer immunotherapy. | — |
| 20 | Aminex Therapeutics Immuno-oncology company developing novel therapies to empower the immune system | $21M | 48 mo ago | Series B | 9 | 2009 | — | — | — |
| 21 | Link Immunotherapeutics Developer of immunotherapeutics to treat cancer | $14M | 67 mo ago | Deadpooled | 15 | 2019 | — | — | — |
| 22 | Orlance Developer of a platform to deliver nucleic acid vaccines and related therapies | $14M | 18 mo ago | Funding Raised | — | 2016 | Kristyn Aalto CEO | 5 patents Patents concentrated in health & consumer products | — |
| 23 | Tria Bioscience Innovating hearing technology for biomedical equipment manufacturers worldwide | $9M | 97 mo ago | Deadpooled | — | 2009 | Christopher Clegg Founder & President | — | — |
| 24 | Neoleukin Therapeutics Manufacturers of therapeutic proteins to treat immunological disorders | $5M | 188 mo ago | Acquired | 7 | 2003 | Jonathan Drachman CEO & President | — | — |
| 25 | Abacus Bioscience Developer of immunotherapeutics for treating cancer and viral diseases | $4M | 45 mo ago | Series A | 7 | 2015 | Edward Clark Founder and Chair | — | — |
| 26 | Alpine Immune Sciences Developer of immunotherapies to treat cancer and autoimmune disorders | $1M | 61 mo ago | Acquired | 126 | 2015 | — | 330 patents Engineered ICOS ligand protein therapeutics for immune modulation | — |
| 27 | MalarVx Developing innovative malaria vaccines using RNA technology and in vitro culture systems | $1M | 73 mo ago | Public | 5 | 2012 | — | 3 patents Malaria vaccine compositions, delivery devices, and sterile protection methods | — |
Top 12 Immunotherapy companies in Seattle
#1
Series B · Seattle, Washington · founded 2021 · 54 employees$93Mraised▾
Manufacturer of cytokine based drugs
- Apr 2026Series B$26.9M
- Nov 2022Series A$93M
#2
Series D · Seattle, Washington · founded 2015 · 33 employees$143.6Mraised▾
Developer of immunotherapies for the treatment of cancer. The company uses a proprietary technology platform to discover human antibodies and an immune checkpoint inhibitor (CPI). The company’s lead candidate is OR2805 for the treatment of multiple tumor types.
- Apr 2025Series D$6M
- May 2023Grant (prize money)$13M
- May 2023Series D$14M
- Feb 2022Conventional Debt$50M
#3
Series C · Seattle, Washington · founded 2019 · 168 employees$263Mraised▾
Developer of cancer therapeutics. The company has developed in vivo cellular immunotherapy platform that uses gene therapy to target and attack cancer cells. The company's products include VivoVec that acts through the body’s lymphatic system, to produce cancer-fighting VivoCAR T cells. The company's proprietary RACR/CAR system is used to enhance the activity of VivoCAR T cells. The company's other product includes TumorTag which is used to tag targeted tumor cells/stromal elements.
- Jan 2025Series C$100M
- Jun 2021Series B$210M
- Nov 2020Series A$53M
#4
Series A · Seattle, Washington · founded 2024$187Mraised▾
Developer of multi-payload antibody-drug conjugates for cancer treatment. It develops next-generation antibody-drug conjugates (ADCs) with differentiated payload and linker technologies. This targeted delivery of drug combinations to tumor cells aims to maximize therapeutic benefit for cancer patients. A key focus is on HER2-targeted dual-payload ADCs, and the company is advancing these through clinical proof-of-concept. Research and early development leverage systems biology approaches. Clinical development programs are managed from initial design through to global regulatory approvals. Business development activities include partnerships across multiple therapeutic areas and modalities.
- Mar 2025Series A$187M
#5
Series B · Seattle, Washington · founded 2017 · 8 employees$86Mraised▾
Developer of vaccines for the treatment of various diseases. The company's product pipeline includes CRV-101, for Herpes Zoster, CRV0-102 used against chicken pox. Other products of the company include CRV-201 used against the respiratory syncytial virus.
- Mar 2025Series B$110M
- Nov 2022Series A$26M
- Jan 2022Series A$60M
#6
Seed · Seattle, Washington · founded 2018 · 32 employees$30.6Mraised▾
HDT Bio is a developer of immunotherapy for the treatment of cancer & infectious diseases. It enhances the body's immunity power to fight against cancer disease. It increases tumor junctions and improves the disruptive capability. It helps in the tumor penetrance and therefore improves the efficacy, of diverse therapeutics including chemotherapeutics like Paclitaxel, Doxil, Cisplatin, antibodies, oncolytic viruses, and cell therapies. It helps in the treatment of breast cancer, ovarian cancer, and many more. It also provides solutions for pathogen agnostic therapeutics that offer solutions against gram-positive and gram-negative bacteria.
- May 2025Grant (prize money)$2.7M
- May 2025Grant (prize money)$1.6M
- May 2025Grant (prize money)$2.2M
- Apr 2025Grant (prize money)$2M
#7
Public · Seattle, Washington · founded 2016 · 45 employees$57.1Mraised▾
Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology. It is using its proprietary Adaptir platform technology to develop immuno-oncology candidates that focus on redirected T-cell cytotoxicity. It generate immunotherapeutics with mechanisms of action including targeted cytokine delivery, targeting two cell surface receptors or neutralization of multiple soluble proteins. Its pipeline has 4 oncology candidates with the lead Otlertuzumab which induces cell death of primary CLL cells-B-cell tumor lines and also induces NK-cell mediated ADCC and macrophage-mediated phagocytosis for chronic lymphocytic leukemia (CLL).
- Apr 2025Post IPO$2.1M
- Jan 2017Venture Debt$20M
- Aug 2016Conventional Debt$35M
#8
Funding Raised · Seattle, Washington · founded 2016$14Mraised▾
Developer of a platform to deliver nucleic acid vaccines and related therapies. it offers MACH-1 a powdered, needle-free nucleic acid vaccines with its epidermal vaccine delivery platform. It uses pressurized gas to accelerate microparticles of vaccines.
- Apr 2025Grant (prize money)$600K
- Apr 2025Grant (prize money)$400K
- May 2024Grant (prize money)$300K
- Sep 2023Grant (prize money)$400K
#9
Series B · Seattle, Washington · founded 2020 · 48 employees$200Mraised▾
Developer of T-cell therapies for cancer treatment. The therapies include cell therapy producing controlled Cytokine X, CAR with counter- exhaustion mechanism, cell therapy producing controlled Cytokine Y, and drug-induced gene regulation. These therapies are developed by combining protein design and cell engineering and also with the help of protein design software that custom designs the new biological functions.
- Jul 2024Series B$144M
- Mar 2021Series A$30M
#10
Series B · Seattle, Washington · founded 2009 · 20 employees$44.1Mraised▾
Developer of programmed B cell therapies for protein delivery. It programs B cells to function as biofactories for therapeutic protein production. The approach involves collecting a patient's B cells and programming them to produce personalized protein therapeutics. These programmed cells are then expanded and infused back into the patient, where they are expected to reside and continuously produce therapeutic proteins.
- May 2024Series B$4.6M
- Jan 2023Grant (prize money)$8M
- Nov 2021Grant (prize money)$4M
- Mar 2021Series B$10.3M
#11
Acquired · Seattle, Washington · founded 2008 · 12 employees$103.5Mraised▾
Kineta is focused on developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases. Autoimmune disease pipeline includes dalazitide in clinical trial phase 1B for Lupus, Psoriasis, Psoriatic Arthritis, RA, MS, Vasculitis, IBD, Asthma, AD, Type 1 diabetes (T1D). Antiviral pipeline includes compounds of preclinical categories innate-immune antivirals, vaccine adjuvants and direct-acting antivirals all of which discovered using its proprietary aviid antiviral discovery platform. It also has a chronic pain candidate in preclinical stage for diabetic nephropathy and traumatic injury
- Jun 2022Series D$17.4M
- Feb 2022Series D$2.4M
- Jun 2021Series D$1.2M
- Jun 2021Series D$17.4M
#12
Public · Seattle, Washington · founded 2016 · 17 employees$211Mraised▾
Silverback Therapeutics is a stealth-mode startup headed by Peter Thompson, MD, University of Washington neurosurgery professor and a partner at Orbimed Ventures. Several members of Silverback’s executive team have formerly held executive positions at Juno Therapeutics. Some of the candidates for clinical trials are SBT6050 that is TLR8 Agonist, SBT6290 bladder cancer, SBT8230 for chronic hepatitis B, etc.
- Sep 2020Series C$85M
- Mar 2020Series B$78.5M
- Sep 2018Series A$37.5M
- Dec 2017Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Immunology in Seattle is moving
A read on the academic research around Immunology in Seattle — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 42 papers.
- Seattle Children\'s Hospital24
- Seattle University10
- Seattle Cancer Care Alliance5
- Seattle Pacific University1
- Seattle Institute for Biomedical and Clinical Research1
- Immunotherapy5
- Chimeric antigen receptor5
- T cell5
- Cancer research3
- Immune system3
- Chimeric antigen receptor1→6
- Myeloid leukemia1→3
- Leukemia1→3
- Immunotherapy5
- Immune system3
- Adverse effect3
- Cancer immunotherapy2
- Cancer2
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.